{"nctId":"NCT00735462","briefTitle":"Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts","startDateStruct":{"date":"2008-08"},"conditions":["Genital Warts"],"count":511,"armGroups":[{"label":"2.5% imiquimod cream","type":"EXPERIMENTAL","interventionNames":["Drug: 2.5% imiquimod cream"]},{"label":"3.75% imiquimod cream","type":"EXPERIMENTAL","interventionNames":["Drug: 3.75% imiquimod cream"]},{"label":"Placebo cream","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo cream"]}],"interventions":[{"name":"2.5% imiquimod cream","otherNames":["2.5% imiquimod topical cream"]},{"name":"3.75% imiquimod cream","otherNames":["3.75% imiquimod topical cream"]},{"name":"Placebo cream","otherNames":["Placebo topical cream"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In good general health\n* Diagnosis of external genital / perianal warts with at least 2 warts and no more than 30 warts\n* Negative pregnancy test (for women who are able to become pregnant)\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating or planning to become pregnant during the study\n* Evidence of clinically significant or unstable disease (such as stroke, heart attack)\n* Have any of the following conditions: HIV infection; current or history of high risk HPV infection (e.g., HPV types 16, 18, etc.); outbreak of herpes genitalia in the wart areas; internal warts requiring or undergoing treatment; dermatological disease (e.g., psoriasis) or skin condition in the wart areas\n* Have received specific treatments in the treatment area(s) within the designated time period prior to study treatment initiation","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study.","description":"The complete clearance was defined as completely cleared all warts including baseline and newly emerged during the study at all anatomic areas.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.248","spread":null},{"groupId":"OG001","value":"0.294","spread":null},{"groupId":"OG002","value":"0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Treatment Related Adverse Reactions (AEs), Any Local Skin Reactions (LSRs), and Number of Subjects Who Took Rest Periods During the Treatment Period","description":"Treatment related defined as \"probably related\" or \"related\" by investigator. Local skin reactions (LSRs)were part of the treatment related adverse events and assessed by the investigators.\n\nRest periods defined as temporary interruption of dosing due to intolerable local skin reaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"148","spread":null},{"groupId":"OG002","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":201},"commonTop":["Application site pain","Application site pruritus","Application site irritation","Application site rash","Application site ulcer"]}}}